ClinicalTrials.gg
RecruitingNCT06307964HepMAHUpdated Feb 10, 2026

Intra-Hepatic Microbiota in Alcoholic Hepatitis

An observational study in Cirrhosis, Alcoholic Liver Disease and Alcoholic Hepatitis, sponsored by Hospices Civils de Lyon. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Primary conditionHepatitis, AlcoholicRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis, Alcoholic
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Hepatitis, Alcoholic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Hospices Civils de Lyon · Observational

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Hepatitis, Alcoholic with a site in France — 5 open to participants now, 5 under way, 1 of them phase 3. Hepatitis, Alcoholic · France.

Started
2024
with 1 other
Observational
3 of 16
3 open now
Registered
14th of 16
by date
Lead sponsor
1 of 16
Hospices Civils de Lyon

Among the 16 studies in Hepatitis, Alcoholic with a site in France, this one is one of 2 that started in 2024, is one of 3 observational ones, and was the 14th registered.

Hepatitis, Alcoholic

114 studies on the registry are indexed under Hepatitis, Alcoholic; 25 are open to participants now.

Browse Hepatitis, Alcoholic studies →

Open to participants now

5 of the 16 studies in Hepatitis, Alcoholic with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 17 Hepatitis, Alcoholic studies recruiting now, 9 (53%) set no upper age limit and 8 (47%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Hepatitis, Alcoholic with a site in France, or all of them as a file.
02

Study summary

Alcoholic hepatitis (AH) is a serious complication of alcoholic liver disease (ALD). The histological presentation of AH is characterized by neutrophilic lobular inflammation, macrovesicular steatosis, hepatocyte ballooning and necrosis and the presence of Mallory bodies. In cases of severe HA, defined by a modified Maddrey score of 32 or above, mortality at 1 month is estimated at between 10 and 50%. The only treatment to reduce early mortality is corticosteroid therapy. However, only 60% of patients respond to corticosteroids, and no benefit has been demonstrated on late mortality. Identifying new therapeutic targets is therefore a major challenge in this disease.

Numerous pre-clinical studies and human data suggest the involvement of the intestinal microbiota in the pathogenesis of AH. Translocation of viable bacteria and microbial products from the digestive tract to the liver contributes to local and systemic inflammation, hepatocyte death and fibrogenesis. However, the intrahepatic microbial environment has never been characterized in HA.

The study hypothesis is that the intrahepatic microbiota is modulated by bacterial translocation and is associated with clinical outcomes.

The aim of this study is to determine the composition of the intrahepatic (obtained from transjugular liver biopsy), blood and fecal microbiota in patients with suspected severe AH from a monocentric prospective cohort in the Hepatology Department at Croix-Rousse Hospital (Lyon). Fifty consecutive patients with clinical suspicion of AH and indication for transjugular liver biopsy will be included. About thirty-five patients are expected in the confirmed AH group, and 15 in the group "alcoholic liver disease with no AH", based on data from the literature. The composition of the various microbiota will be determined by sequencing the 16S rRNA gene, and the results will be correlated with clinical data (corticosteroid sensitivity, overall survival, transplant-free survival, MELD score in particular) and histological data.

This exploratory study will enable to analyze the intra-hepatic microbiota, and to study its link with intra-hepatic inflammation and the clinical course of patients with AH. The data generated by HepMAH will thus help identify potential new therapeutic targets linked to the gut microbiota, and provide a scientific basis for the development of therapeutic interventions targeting the microbiota in HA.

03

Conditions studied

  • Cirrhosis
  • Alcoholic Liver Disease
  • Alcoholic Hepatitis

Browse trials for

Keywords

  • alcoholic hepatis
  • bacterial translocation
  • microbiota
  • 16S rRNA
  • intra-hepatic microbiota
  • cirrhosis
  • alcoholic liver disease
04

In context

Hepatitis, Alcoholic Reclassified

114 studies on the registry are indexed under Hepatitis, Alcoholic; 25 are open to participants now.

This study's planned enrollment of 50 is below the median of 230 across 28 observational studies indexed under Hepatitis, Alcoholic.

Browse Hepatitis, Alcoholic studies →

Lead sponsor

Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.

Compared within Hepatitis, Alcoholic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A prospective observational multicentric cohort will be conducted at Croix Rousse Hospital (Lyon, France), in the Hepatology and Intensive Care Units.

Fifty consecutive patients hospitalized in either of these units for clinical suspicion of alcoholic hepatitis and indication for transjugular liver biopsy will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients suffering from alcoholic liver disease and clinical suspicion of alcoholic hepatitis (subacute jaundice, heavy alcohol consumption active or weaned for ≤ 3 months, modified Maddrey score ≥32) and indication for diagnostic transjugular liver ;
  • Non-objection obtained from the patient or trusted person in case of impaired judgment or consciousness before performing liver biopsy;
  • Aged ≥ 18 years at the time of study entry;

Exclusion criteria

Exclusion Criteria:

  • Patients who were treated with antibiotics or probiotics between the 15th day and 72 hours prior to liver , with the exception of antibiotics used for the prophylaxis of ascites infection or hepatic encephalopathy
  • to transjugular liver biopsy (hepatocellular carcinoma on predicted puncture site)
  • Pregnant, parturient or breast-feeding women
  • Persons deprived of their liberty by judicial or administrative decision
  • Adults under legal protection (guardianship, curators)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Alcoholic hepatitis

    Patients with histologically proven AH (after transjugular liver biopsy procedure and histological assessment).

    Procedure: Biological sampling

  • No alcoholic hepatitis

    Patients with initially suspected AH (excessive alcohol consumption and modified Maddrey score \> 32) but no AH at the histological evaluation of liver biopsy. It corresponds to patients with decompensated alcoholic liver disease but no AH.

    Procedure: Biological sampling

Interventions

  • ProcedureBiological sampling

    * A fragment of the diagnostic transjugular liver biopsy (D0) * Plasma samples at D0, and at 1 and 6 months after liver biopsy if possible * Fecal samples at D0, and at 1 and 6 months after liver biopsy if possible

07

What researchers measure

Primary outcomes

  1. Microbiota composition

    Intrahepatic, blood and fecal microbiota composition will be assessed by 16S rRNA sequencing (MiSeq Illumina). Microbiota analysis will be performed on the fragment of transjugular liver biopsy collected for the purpose of the study, and on plasma and fecal samples after bacterial DNA extraction. Bioinformatics analysis will be carried out using Qiime2, LeFSE (Conda) and the Maaslin2 package (v3.16; R software). Microbiota profiles determined at the genus taxonomic level will be compared between the two groups (proven AH and no AH).

    Time frame: At Day 0, 1 month and 6 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jan 2028, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2024
First posted
Mar 13, 2024
StartActual
Jul 23, 2024
Primary completionEst.
Jan 23, 2028
CompletionEst.
Jul 23, 2028
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06307964
Responsible party
Sponsor
First posted
Mar 13, 2024
Start date
Jul 23, 2024
Primary completion
Jan 23, 2028 (estimated)
Completion
Jul 23, 2028 (estimated)
Last update
Feb 10, 2026

Study contacts

François VILLERET, M.D., Ph.D.
Contact
francois.villeret@chu-lyon.fr
+33426109382
François VILLERET, M.D., Ph.D.
study chair · Hospices Civils de Lyon, Croix Rousse Hospital, Hepatology department

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion